These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 897743)
21. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Al-Hashimi I Drugs Aging; 2005; 22(11):887-99. PubMed ID: 16323968 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome. Noaiseh G; Baker JF; Vivino FB Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774 [TBL] [Abstract][Full Text] [Related]
23. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. Kasama T; Shiozawa F; Isozaki T; Matsunawa M; Wakabayashi K; Odai T; Yajima N; Miwa Y; Negishi M; Ide H Mod Rheumatol; 2008; 18(5):455-9. PubMed ID: 18478182 [TBL] [Abstract][Full Text] [Related]
24. Significance and Implications of Patient-reported Xerostomia in Sjögren's Syndrome: Findings From the National Institutes of Health Cohort. Billings M; Dye BA; Iafolla T; Baer AN; Grisius M; Alevizos I EBioMedicine; 2016 Oct; 12():270-279. PubMed ID: 27639822 [TBL] [Abstract][Full Text] [Related]
25. Re: Researchers make slow headway in managing dry mouth. LeVeque F J Natl Cancer Inst; 1997 Dec; 89(24):1894-5. PubMed ID: 9414180 [No Abstract] [Full Text] [Related]
26. Keratoconjunctitis sicca versus dry mouth and autoantibodies in primary and secondary Sjögren's syndrome. Kitagawa K; Nakamura T; Sugai S Adv Exp Med Biol; 2002; 506(Pt B):1195-9. PubMed ID: 12614051 [No Abstract] [Full Text] [Related]
27. Salivary scintigraphy for Sjögren's syndrome in patients with xerostomia: A retrospective study. Nadal M; Levy M; Bakhsh A; Joly A; Maruani A; Vaillant L; Erra B; Samimi M Oral Dis; 2018 May; 24(4):552-560. PubMed ID: 29117464 [TBL] [Abstract][Full Text] [Related]
28. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems. Arisawa H; Fukui K; Masunaga H Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642 [TBL] [Abstract][Full Text] [Related]
29. Oral symptoms and oral function in people with Sjögren's syndrome. Epstein JB; Villines DC; Sroussi HY Clin Exp Rheumatol; 2015; 33(1):132-3. PubMed ID: 25572418 [No Abstract] [Full Text] [Related]
30. Pilocarpine toxicity and the treatment of xerostomia. Hendrickson RG; Morocco AP; Greenberg MI J Emerg Med; 2004 May; 26(4):429-32. PubMed ID: 15093850 [TBL] [Abstract][Full Text] [Related]
31. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects. Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964 [TBL] [Abstract][Full Text] [Related]
32. Diagnosis of Sjögren's syndrome from a xerostomia case accompanied by multiple dental caries. Seo DG; Kim J; Lee CY; Park SH Oper Dent; 2009; 34(3):359-64. PubMed ID: 19544828 [No Abstract] [Full Text] [Related]
33. [Treatment of oral dryness in Sjögren's syndrome]. Mariette X Rev Med Interne; 2004 Apr; 25(4):287-93. PubMed ID: 15112663 [TBL] [Abstract][Full Text] [Related]
34. Long-term low-dose glucocorticoid therapy associated with remission of overt renal tubular acidosis in Sjögren's syndrome. el-Mallakh RS; Bryan RK; Masi AT; Kelly CE; Rakowski KJ Am J Med; 1985 Oct; 79(4):509-14. PubMed ID: 4050835 [TBL] [Abstract][Full Text] [Related]
35. Primary Sjögren's syndrome. Sawyer S Nurs Stand; 2004 Feb 18-24; 18(23):33-6. PubMed ID: 15017814 [TBL] [Abstract][Full Text] [Related]